The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | IKEMA: isatuximab + Kd improves response and PFS in R/R myeloma
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, gives an update on the ongoing IKEMA study (NCT03275285), a Phase III trial investigating isatuximab plus carfilzomib and dexamethasone (Isa-Kd) versus carfilzomib and dexamethasone (Kd) for patients with relapsed/refractory (R/R) multiple myeloma. Isatuximab is a monoclonal antibody therapy targeting CD38. A very good partial response or better was achieved in 72.6% of patients receiving Isa-Kd treatment versus 56.1% receiving Kd treatment alone. Progression-free survival (PFS) was not reached at a median follow-up of 20.7 months for patients treated with Isa-Kd versus PFS at 19.15 months for patients treated with Kd. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research funding to institution: Sanofi, Janssen, AMGEN
Consultancy: GSK
